Roche secured global rights to a Rona Therapeutics RNA interference drug targeting ALK7—adding to a fast-growing ALK7 obesity race that also includes GSK and Arrowhead Pharmaceuticals. Roche will pay $100 million for the rights, betting on a genetically validated pathway for visceral-fat reduction and broader metabolic indications. The move reflects continued investor and payer focus on dose-optimized, differentiated anti-obesity mechanisms beyond GLP-1 class products. With multiple companies now pursuing ALK7 inhibition strategies, early differentiation will likely come from tolerability, liver/metabolic biomarker readouts, and proof-of-mechanism translating from genetics to humans.